In a Japanese phase III trial reported in the Journal of Clinical Oncology, Kenmotsu et al found that adjuvant irinotecan/cisplatin did not improve relapse-free survival vs etoposide/cisplatin in patients with completely resected, pathologic stage I–IIIA, high-grade neuroendocrine carcinoma of the lung.
A new study published by Stacey A. Fedewa, PhD, and colleagues in JNCI: Journal of the National Cancer Institute found that state-level lung cancer screening rates were not aligned with the national lung cancer burden. The report provides the first population-based state-level screening data for all 50 states and notes lung cancer screening rates varied geographically by state.
"In the year 2020 alone, the U.S. Food and Drug Administration approved nine new indications for lung cancer; four represented novel agents approved for the first time (selpercatinib, pralsetinib, lurbinectedin, capmatinib), and three were new indications for immunotherapy agents. In all, the treatment of NSCLC has been transformed in the past few years," writes Suresh S. Ramalingam, MD, FACP, FASCO.
In an article published in The Lancet Oncology, Redman et al described the conduct of and findings from the Lung Cancer Master Protocol, a completed biomarker-driven master protocol designed to address the need for improved therapies for previously treated patients with squamous non–small cell lung cancer (NSCLC).
In a retrospective cohort study reported in JAMA Oncology, Shankar et al found improved progression-free and overall survival among patients who experienced multisystem immune-related adverse events after anti–PD-1 or anti–PD-L1 immune checkpoint inhibitor therapy for stage III/IV non–small cell lung cancer (NSCLC).